Dietary strategies for allergy prevention in children

There is still no treatment that can fully cure children with asthma and allergic diseases. Treatments are concentrated on tackling the symptoms. The symptoms can thus be relieved but the treatments usually have to be taken by patients for very long periods of time or even their whole lives. The best long-term therapy is still the avoidance of the causative allergen, e.g. certain foods.

As yet no effective strategies for preventing allergies have been found by researchers. There is hence a need to develop new approaches.

The prevention of allergies by means of diet in early childhood is one such approach that deserves consideration. Until recently prevention simply involved advising people to avoid certain foods, especially in infancy and early childhood. However, the latest recommendations no longer point in this direction. This is because it has not been proved that leaving out certain foods or introducing them at a later stage can actually prevent allergies. On the contrary, new proposals concentrate on the fact that early contact with allergens can induce immune tolerance. For instance, a time window might be opened in early childhood for preventing the development of allergies.

In our study on farmers’ children (PASTURE/EFRAIM) we have already shown that varied baby food in the first year of life reduces the risk of atopic dermatitis. We also demonstrated the same effect for asthma, food allergy and allergic sensitisation. Independently of these findings, we were also able to show the protective effect of supplementary baby food, mainly dairy products (e.g. yoghurt), introduced in the first year of life (as described in the Newsletter of October 2012).

Our findings from the farmers’ children study support the hypothesis that early contact with different allergens in the child’s intestinal tract is necessary for immune tolerance to develop. The nature of the diet, the gut flora and the immune response are closely interconnected. One possible explanation for the protective effect might be the early colonisation of the gut with microbes and their metabolic products. It has already been shown that what are known as short-chain fatty acids, metabolic products of certain intestinal bacteria, have an anti-inflammatory effect. These short chain fatty acids are generated by the fermentation of carbohydrates in the intestinal tract but they are also contained in food. One of these fatty acids, butyrate, is found in the triglycerides of cow’s milk. Therefore the natural butyrate content is high in dairy products.

We observed the preventive effect of short-chain fatty acids for the first time in the mouse model of allergic respiratory inflammation (similar to asthma).We gave the short-chain fatty acids orally to the mice throughout the duration of the experiment. In a healthy lung there are normally only a few macrophages passing through the lung. As soon as an allergy is triggered, the cell count in the lung rises sharply, which is mainly due to the migration of eosinophilic cells. We flushed out the lungs of mice in our allergy model and counted the cells they contained. We were able to demonstrate that the administration of short-chain fatty acids can markedly reduce the number of cells contained in the bronchoalveolar lavage (BAL, washing out the lung).

Messengers typical of an allergy also decrease markedly due to the administration of short-chain fatty acids, which further confirms the protective effect of these fatty acids in allergy.

These promising results in the mouse model have prompted us to tackle further projects along these lines. There are plans to administer short-chain fatty acids in combination with a butyrate boosting substrate as well as butyrate-producing probiotics.

In the study on farmers’ children we plan to investigate the level of short-chain fatty acids in stool samples from the first year of life. The link between fatty acid content and diet is to be investigated.

The results outlined above point to possible avenues for developing effective dietary strategies for the prevention of allergic diseases.

Prof. Dr. Kilian Eyerich is our new member of the Scientific Board

As of November 2025, we welcome Prof. Dr. Kilian Eyerich as a new member of our Scientific Board.
Prof. Dr. Kilian Eyerich is the Medical Director of the Department of Dermatology and Venereology at the University Medical Center Freiburg.
With his appointment to our board, the University of Freiburg becomes an additional research center within the CK-CARE consortium.

The Freiburg site strengthens the research network with its outstanding expertise in T-cell immunology, with a particular focus on tissue-resident memory T cells and their role in the development and persistence of atopic dermatitis. The team aims to apply T-cell–targeted therapies even more precisely in the future and thereby sustainably influence immunological memory in a positive way.

At the core of their work is the recruitment of patients as well as the collection and integration of data and samples from the ProRaD study, a prospective longitudinal study investigating the remission phase of atopic dermatitis and other allergy-associated diseases such as asthma, food allergies, and allergic rhinitis.

We look forward to a successful collaboration and warmly welcome Kilian Eyerich and his team to the CK-CARE consortium.

5th Global Allergy Forum in Davos: Allergy and Environment in Focus

From October 16–18, 2025, more than 70 international experts gathered at the Medicine Campus Davos for the 5th Global Allergy Forum. Under the theme “Allergy and Environment – Loss of Balance and Ways to Restore It”, participants explored how environmental factors drive the rise of allergic diseases and discussed innovative strategies to restore immune balance. Key topics included nutrition and environmental exposures, the role of skin and mucosal barriers, psychoneuroimmunology, and the use of artificial intelligence in allergy research. The forum’s conclusions will be summarized in the upcoming “Davos Declaration.”

More here

New Publication in Allergy: From Disease Control to Disease Modification – The Atopic Dermatitis Disease Activity Index

“New and advanced treatments for atopic dermatitis (AD) are moving beyond just managing symptoms. For some patients, these therapies can modify the disease itself, potentially leading to long-term remission (“deep remission”) even after stopping medication. This new treatment goal is called “disease modification.” The aim is to fundamentally change the course of AD and its related health conditions, offering transformative and lasting relief. However, optimal measurement of deep remission remains a key challenge for clinicians, researchers, regulators, and ultimately the payers. Our recent publication in Allergy discussing the Atopic Dermatitis Disease Activity Index (ADDAI), a composite tool to help determine if a treatment has successfully achieved true disease modification, helping doctors and patients know if the right treatment approach has been found. (link to publication).

From Disease Control to Disease Modification: The AtopicDermatitis Disease Activity Index

New Study Published in Nutrients: Diet Diversity and Adherence to a Mediterranean Diet Pattern in Pregnancy Is Protective Against the Development of Early-Childhood Atopic Dermatitis

We are proud to share our latest paper published in Nutrients by the CK-CARE Consortium:

read study

This study, conducted within the CARE birth cohort, provides new insights into how maternal nutrition during pregnancy influences the development of atopic dermatitis in early childhood.

Key findings:

  • A Mediterranean diet during pregnancy significantly reduces the risk of early childhood AD.
  • Greater dietary diversity is also associated with a lower AD risk.
  • In contrast, frequent red meat consumption correlates with persistent AD symptoms.

These results underscore the importance of nutritional patterns—not just individual nutrients—in shaping immune development and allergic disease susceptibility.

Congratulations to the research team as well as all members of the CK-CARE study group and our international collaborators.

At CK-CARE, we are committed to advancing prevention strategies for allergic diseases through interdisciplinary and translational research. This study highlights the critical window of opportunity during pregnancy for long-term immune health.

Peter Schmid-Grendelmeier received the EAACI Clinical Fellow Award 2025

On June 13, 2025, at the EAACI Congress in Glasgow, Peter Schmid-Grendelmeier was honored with the EAACI Clinical Fellow Award 2025. He is the first Dermatologist to receive this prestigious recognition.

We are proud to have Peter Schmid-Grendelmeier as part of our CK-CARE team and to benefit from his outstanding scientific work and extensive expertise. We warmly congratulate him on this well-deserved award!

Atopic Dermatitis and Cardiovascular Disease

Atopic Dermatitis and Cardiovascular Disease – a deeper connection?
As part of our ongoing commitment to advancing the understanding of chronic inflammatory diseases, we at CK-CARE are proud to share the results of a newly published study in *Allergy* from our multicenter ProRaD research initiative.
Read the full publication: https://doi.org/10.1111/all.16588